Three quick notes:
1. The antitrust issues stem from the foot and ankle offerings, since Wright Medical focuses on the lower extremities and small bones.
2. Larry Biegelsen, a senior analyst at Wells Fargo, thinks Stryker will divest Wright Medical’s STAR ankle business, which has 70 percent share in the total ankle replacement market.
3. Premarket on Nov. 4, Wright Medical stock was up 31 percent while Stryker was down 3 percent.
More articles on orthopedic devices:
Smith+Nephew Q3 revenue up 6.5% to $1.2B: 5 key notes
Alphatec posts Q3 loss—6 insights
Conformis revenue down 40% in Q3, net loss hits $8.7M: 5 details
